The Experts below are selected from a list of 69 Experts worldwide ranked by ideXlab platform
Shozo Fujino - One of the best experts on this subject based on the ideXlab platform.
-
a phase ii study of docetaxel plus nedaplatin in patients with metastatic non small cell lung cancer
Cancer Chemotherapy and Pharmacology, 2012Co-Authors: Koji Teramoto, Yoshikuni Asada, Noriaki Tezuka, Shuhei Inoue, Shozo Fujino, Yoshitomo Ozaki, Yuji Suzumura, Yasutaka Nakano, Satoru SawaiAbstract:Purpose Nedaplatin is a Cisplatin Derivative, which has similar activity to Cisplatin in non-small-cell lung cancer (NSCLC) when combined with vindesine, and causes less nausea/vomiting and nephrotoxicity compared with Cisplatin. The aim of this study was to evaluate the efficacy and safety of combination chemotherapy with docetaxel plus nedaplatin in patients with metastatic NSCLC.
Junzo Kigawa - One of the best experts on this subject based on the ideXlab platform.
-
Nedaplatin: a Cisplatin Derivative in cancer chemotherapy.
Cancer management and research, 2013Co-Authors: Muneaki Shimada, Hiroaki Itamochi, Junzo KigawaAbstract:Nedaplatin, a Cisplatin analog, has been developed to decrease the toxicities induced by Cisplatin, such as nephrotoxicity and gastrointestinal toxicity. The dose of nedaplatin is determined by body surface area, not by the area under the curve (AUC). The recommended therapeutic dose is 80–100 mg/m2, although the pharmacokinetic profile of nedaplatin is similar to that of carboplatin. In our preliminary study, there was a favorable correlation between AUC and creatinine clearance (CL), suggesting that renal function should be considered when nedaplatin is administered. Ishibashi’s formula, ie, DoseNDP = AUC × CLNDP, where CLNDP = 0.0738 × creatinine clearance + 4.47, would be predictable and useful for estimating the individual dose of nedaplatin. Several Phase II studies have suggested that nedaplatin might be a useful second analog, especially for patients with non-small cell lung cancer, esophageal cancer, uterine cervical cancer, head and neck cancer, or urothelial cancer. Further, nedaplatin was reported to be a useful chemotherapeutic agent with radiosensitizing properties; however, there is no Phase III study of nedaplatin, neither with chemotherapy nor with concurrent chemoradiotherapy, because nedaplatin is not commonly used throughout the world. Further evaluation in a randomized controlled trial is warranted to demonstrate definitively the activity of nedaplatin.
Kazuo Maruyama - One of the best experts on this subject based on the ideXlab platform.
-
effective anti tumor activity of oxaliplatin encapsulated in transferrin peg liposome
International Journal of Pharmaceutics, 2008Co-Authors: Ryo Suzuki, Tomoko Takizawa, Yasuhiro Kuwata, Mahito Mutoh, Nobuyuki Ishiguro, Naoki Utoguchi, Atsuko Shinohara, Masazumi Eriguchi, Hironobu Yanagie, Kazuo MaruyamaAbstract:Oxaliplatin (trans-L-diaminocyclohexane oxalatoplatinum, L-OHP) is a novel Cisplatin Derivative that can improve the side effects of Cisplatin such as toxicity to the kidneys and peripheral nerve system. However, L-OHP is effective only when combined with 5-Fluorouracil (5-FU) and Leucovorin. The relatively low anti-tumor index of L-OHP alone is because low levels accumulate in tumor tissues due to high partitioning to erythrocytes in vivo. A successful outcome of cancer therapy using L-OHP requires the selective delivery of a relatively high concentration of the drug to tumors. The present study examines tumor-selective delivery of L-OHP using liposomes modified with transferrin-conjugated polyethyleneglycol (TF-PEG-liposomes). Delivery using these liposomes significantly reduced L-OHP partitioning to erythrocytes and improved the circulation time of L-OHP in vivo, resulting in enhanced extravasation of liposomes into tumors. The TF-PEG-liposomes maintained a high L-OHP concentration in tumors for over 72 h after intravenous injection, which was longer than that of the liposomes modified with PEG (PEG-liposomes). Intravenously administered L-OHP encapsulated within TF-PEG-liposomes (L-OHP: 5 mg/kg) suppressed tumor growth more effectively than PEG-liposomes, Bare-liposomes and free L-OHP. Although L-OHP is usually combined with 5-FU and Leucovorin, our results suggest that L-OHP encapsulated within TF-PEG-liposomes has potential for cancer therapy.
-
effective anti tumor activity of oxaliplatin encapsulated in transferrin peg liposome
International Journal of Pharmaceutics, 2008Co-Authors: Ryo Suzuki, Tomoko Takizawa, Yasuhiro Kuwata, Mahito Mutoh, Nobuyuki Ishiguro, Naoki Utoguchi, Atsuko Shinohara, Masazumi Eriguchi, Hironobu Yanagie, Kazuo MaruyamaAbstract:Abstract Oxaliplatin ( trans - l -diaminocyclohexane oxalatoplatinum, l -OHP) is a novel Cisplatin Derivative that can improve the side effects of Cisplatin such as toxicity to the kidneys and peripheral nerve system. However, l -OHP is effective only when combined with 5-Fluorouracil (5-FU) and Leucovorin. The relatively low anti-tumor index of l -OHP alone is because low levels accumulate in tumor tissues due to high partitioning to erythrocytes in vivo . A successful outcome of cancer therapy using l -OHP requires the selective delivery of a relatively high concentration of the drug to tumors. The present study examines tumor-selective delivery of l -OHP using liposomes modified with transferrin-conjugated polyethyleneglycol (TF–PEG-liposomes). Delivery using these liposomes significantly reduced l -OHP partitioning to erythrocytes and improved the circulation time of l -OHP in vivo , resulting in enhanced extravasation of liposomes into tumors. The TF–PEG-liposomes maintained a high l -OHP concentration in tumors for over 72 h after intravenous injection, which was longer than that of the liposomes modified with PEG (PEG-liposomes). Intravenously administered l -OHP encapsulated within TF–PEG-liposomes ( l -OHP: 5 mg/kg) suppressed tumor growth more effectively than PEG-liposomes, Bare-liposomes and free l -OHP. Although l -OHP is usually combined with 5-FU and Leucovorin, our results suggest that l -OHP encapsulated within TF–PEG-liposomes has potential for cancer therapy.
Muneaki Shimada - One of the best experts on this subject based on the ideXlab platform.
-
Nedaplatin: a Cisplatin Derivative in cancer chemotherapy.
Cancer management and research, 2013Co-Authors: Muneaki Shimada, Hiroaki Itamochi, Junzo KigawaAbstract:Nedaplatin, a Cisplatin analog, has been developed to decrease the toxicities induced by Cisplatin, such as nephrotoxicity and gastrointestinal toxicity. The dose of nedaplatin is determined by body surface area, not by the area under the curve (AUC). The recommended therapeutic dose is 80–100 mg/m2, although the pharmacokinetic profile of nedaplatin is similar to that of carboplatin. In our preliminary study, there was a favorable correlation between AUC and creatinine clearance (CL), suggesting that renal function should be considered when nedaplatin is administered. Ishibashi’s formula, ie, DoseNDP = AUC × CLNDP, where CLNDP = 0.0738 × creatinine clearance + 4.47, would be predictable and useful for estimating the individual dose of nedaplatin. Several Phase II studies have suggested that nedaplatin might be a useful second analog, especially for patients with non-small cell lung cancer, esophageal cancer, uterine cervical cancer, head and neck cancer, or urothelial cancer. Further, nedaplatin was reported to be a useful chemotherapeutic agent with radiosensitizing properties; however, there is no Phase III study of nedaplatin, neither with chemotherapy nor with concurrent chemoradiotherapy, because nedaplatin is not commonly used throughout the world. Further evaluation in a randomized controlled trial is warranted to demonstrate definitively the activity of nedaplatin.
Anthony J Di Pasqua - One of the best experts on this subject based on the ideXlab platform.
-
platinum iv Cisplatin Derivative trans cis cis bis heptanoato amine cyclohexylamine dichloridoplatinum iv has an enhanced therapeutic index compared to Cisplatin for the treatment of non small cell lung cancer
Inorganica Chimica Acta, 2014Co-Authors: Bhuvaneswari Koneru, Warren Redfearn, Michael L Miller, Lara Myers, Anthony J Di PasquaAbstract:Lung cancer is the leading cause of cancer-related death in the United States, and non-small cell lung cancer (NSCLC) the most common type. Platinum (Pt) anticancer agents, such as Cisplatin, remain a mainstay in the clinic; however, these agents are not tumor-specific and, thus, the patient experiences negative side-effects. We here prepare trans, cis, cis-bis(heptanoato)amine(cyclohexylamine)dichloridoplatinum(IV) and demonstrate that it is greater than 50-fold more toxic toward NSCLC cells than is Cisplatin. Furthermore, it has a much improved therapeutic index. This Pt(IV) complex binds to DNA in a manner similar to that of Cisplatin, and can be incorporated into mesoporous silica nanoparticles for fine-controlled release and the targeting of tumors.